Invasive Candidiasis Clinical Trial
Official title:
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp in patients ≥ 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. Patients will be treated with ibrexafungerp for up to 180 days. Treatment beyond 180 days and combination therapy with other antifungal agents may be allowed under special circumstances to be agreed upon by the Investigator and the Sponsor. Subjects must have a proven or probable fungal disease and meet all study criteria to be considered for enrollment. Eligible subjects must also have documented evidence of failure of, intolerance to, or toxicity related to a currently approved SoC antifungal treatment. Subjects will also be considered for enrollment if they have an eligible fungal disease and, in the judgement of the investigator, the subject cannot receive approved oral antifungal options (e.g. susceptibility of the organism or risk for drug-drug interactions) and a continued IV antifungal therapy is not desirable or feasible due to clinical or logistical circumstances. Following a screening visit, there will be up to 15 treatment visits, a follow-up visit and 2 follow-up contacts. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05763251 -
Comparison of Uncomplicated Candidemia Therapy Duration in Children
|
N/A | |
Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
Completed |
NCT02491151 -
Variability of Fluconazole Concentration in Critically Ill Patients
|
N/A | |
Completed |
NCT01716988 -
Pharmacokinetics of Micafungin in Critically Ill Patients
|
N/A | |
Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00786903 -
Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?
|
N/A | |
Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 | |
Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
Recruiting |
NCT03538912 -
Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
|
N/A | |
Completed |
NCT02801682 -
NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
|
||
Completed |
NCT02164890 -
Pharmacokinetics of Micafungin in Patients of Intensive Care Units
|
Phase 4 | |
Completed |
NCT02841501 -
Genetic Susceptibility Factors for Candidemia.
|
||
Completed |
NCT01047267 -
Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT00672841 -
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
|
N/A | |
Completed |
NCT02734862 -
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
|
Phase 2 | |
Completed |
NCT01773876 -
Empirical Antifungal Treatment in ICUS
|
Phase 3 | |
Completed |
NCT00689338 -
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
|
Phase 3 |